CTRI/2026/07/113626进行中（未招募）不适用
Effectiveness of Topical Anthocyanin-Rich Blueberry Chitosan Nanoemulgel in management of Oral Leukoplakia: A Clinical Trial - BLUE-OL Trial
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 34
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- 干预性
入排标准
入选标准
- Oral leukoplakia Van der Waal Stage I and Stage II lesions.
- Patients who have not undergone any previous treatment for oral leukoplakia.
- Patients willing to provide written informed consent.
- Patients willing to attend follow up visits at baseline, 15th day and 30th day.
排除标准
- Oral leukoplakia Van der Waal Stage III and Stage IV lesions.
- Patients with other oral potentially malignant disorders.
- Patients with histopathological evidence of severe dysplasia or malignancy.
- Pregnant and lactating women.
- Patients allergic to anthocyanin, chitosan or tretinoin.
- Patients with uncontrolled systemic disease or immunocompromised status.
研究组 & 干预措施
Intervention1: Anthocyanin Rich Blueberry Chitosan Nanoemulgel: Topical application of anthocyanin rich blueberry chitosan nanoemulgel over the oral leukoplakia lesion twice daily for 30 days
干预措施: Intervention1: Anthocyanin Rich Blueberry Chitosan Nanoemulgel: Topical application of anthocyanin rich blueberry chitosan nanoemulgel over the oral leukoplakia lesion twice daily for 30 days
研究者
标识符
- CTRI 编号
- CTRI/2026/07/113626
日期
- 首次发布
- (2个月前)
- 最近更新
- (上个月)
监管与共享
- 是否有结果
- 否